InfuSystem Holdings, Inc(INFU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,300 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
INFU Stock Analysis & AI Quality Score
AI stock analysis and institutional research for InfuSystem Holdings, Inc (INFU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INFU at 53.1/100 on a 32-signal composite quality model, placing it at rank #1,300 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include revenue scale (20.6) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), InfuSystem Holdings, Inc reports quarterly revenue of $33.7M, net income of $1.0M, an operating margin of 4.7%. Top institutional holders of INFU by reported 13-F value include Minerva Advisors, VANGUARD CAPITAL MANAGEMENT, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT,, based on the most recent SEC filings. INFU trades on the NYSE exchange and files with the SEC under CIK 1337013. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INFU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InfuSystem Holdings, Inc directly from SEC EDGAR. InfuSystem Holdings, Inc's 13F Pro composite quality score has ranged between 36 and 67 since 2021, currently 53.1 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.
Revenue
Q1 2026
$33.7M
Net Income
Q1 2026
$1.0M
Free Cash Flow
Q1 2026
$813.0K
Operating Margin
Q1 2026
4.7%
D/E Ratio
Q1 2026
0.33
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+6.4% YoYNet Income
+182.6% YoYOperating Income
+73.0% YoYEPS (Diluted)
+181.8% YoYTotal Assets
-2.9% YoYTotal Debt
-17.8% YoYOp. Cash Flow
+19.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $143.4M +6.4% | $134.9M +7.2% | $125.8M +14.4% | $109.9M +7.4% | $102.4M +5.1% | $97.4M |
| Net Income | $6.6M +182.6% | $2.3M +168.9% | $872.0K +4744.4% | $18.0K -98.7% | $1.4M -91.8% | $17.3M |
| Operating Income | $11.9M +73.0% | $6.9M +68.6% | $4.1M +147.2% | $1.7M -41.3% | $2.8M -68.1% | $8.8M |
| EPS (Diluted) | $0.31 +181.8% | $0.11 +175.0% | $0.04 | $0.00 -100.0% | $0.06 -92.5% | $0.80 |
| Total Assets | $100.6M -2.9% | $103.6M +0.7% | $102.9M +3.5% | $99.4M +1.8% | $97.6M +0.6% | $97.0M |
| Total Debt | $19.6M -17.8% | $23.9M -18.0% | $29.1M -12.2% | $33.2M -0.9% | $33.4M -30.6% | $48.2M |
| Operating Cash Flow | $24.4M +19.3% | $20.5M +82.3% | $11.2M -35.9% | $17.5M -4.4% | $18.3M -9.7% | $20.3M |
AI Insight: INFU Financial Trends
InfuSystem's debt has nearly halved from $34M to $20M over seven quarters, but Q1 2026 shows a seasonal dip in operating cash flow to just $1M.
• Total debt declined from $34M in Q2 2024 to $20M in Q1 2026, a 41% reduction over seven quarters.
• Operating income improved from $2M in Q2 2024 to $4M by Q3–Q4 2025, though it slipped back to $2M in Q1 2026.
• Revenue growth has been modest, ranging narrowly between $34M and $36M across all eight quarters with no clear acceleration.
⚠ Operating cash flow collapsed to $1M in Q1 2026 from $7M in Q4 2025 — weakest reading in four quarters.
⚠ Equity has been range-bound at $53M–$59M despite debt paydown, suggesting limited retained earnings accumulation.
AI Insight: INFU Ratio Trends
Q1 seasonality masks a genuine profitability step-up: ROIC has nearly doubled from 8.5% in Q2 2024 to a TTM 16.4%, while D/E has halved to 0.33.
• ROIC expanded from 8.5% in Q2 2024 to 20.0% in Q3 2025, with TTM settling at 16.4% — a structural improvement.
• D/E ratio declined from 0.64 in Q2 2024 to 0.33 in Q1 2026, signaling consistent deleveraging over five quarters.
• Operating margin ranged 10.2%–10.5% across Q2–Q4 2025, suggesting a durable mid-teens operating floor when seasonality is absent.
⚠ Q1 operating margin collapsed to 1.8% in Q1 2025 and 4.7% in Q1 2026 — Q1 seasonal weakness is deep and recurring.
⚠ Q1 2025 produced negative NPM (-0.8%) and ROE (-1.9%); Q1 2026 recovered slightly but remains well below non-Q1 quarters.
Get alerted when INFU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for InfuSystem Holdings, Inc including:
Top Institutional Holders of INFU
Minerva Advisors LLC
$11.1M1,204,105 shVANGUARD CAPITAL MANAGEMENT LLC
$7.9M860,263 shPUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$7.7M837,925 shFirst Eagle Investment Management, LLC
$6.7M721,371 shBlackRock, Inc.
$5.7M616,586 shDIMENSIONAL FUND ADVISORS LP
$5.5M594,288 shRENAISSANCE TECHNOLOGIES LLC
$5.2M566,809 shHEARTLAND ADVISORS INC
$4.7M510,000 shAMERICAN CENTURY COMPANIES INC
$4.4M473,021 shMeros Investment Management, LP
$4.3M469,408 sh
| Fund | Value | Shares |
|---|---|---|
| Minerva Advisors LLC | $11.1M | 1,204,105 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.9M | 860,263 |
| PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. | $7.7M | 837,925 |
| First Eagle Investment Management, LLC | $6.7M | 721,371 |
| BlackRock, Inc. | $5.7M | 616,586 |
| DIMENSIONAL FUND ADVISORS LP | $5.5M | 594,288 |
| RENAISSANCE TECHNOLOGIES LLC | $5.2M | 566,809 |
| HEARTLAND ADVISORS INC | $4.7M | 510,000 |
| AMERICAN CENTURY COMPANIES INC | $4.4M | 473,021 |
| Meros Investment Management, LP | $4.3M | 469,408 |
More Healthcare Companies
View all Healthcare →Put INFU on your watchlist
Track score changes the day InfuSystem Holdings, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INFU a good stock to buy?
13F Pro's AI-powered analysis of InfuSystem Holdings, Inc (INFU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INFU are available on the INFU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INFU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INFU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InfuSystem Holdings, Inc's investment landscape.